Synthetic Lethality Patents

Synthetic lethality oncology patents cover synthetic-lethal-target innovations; inhibitor-composition innovations; biomarker/patient-selection innovations; and screening-platform and combination/resistance innovations — with IP held by precision-oncology pharma and synthetic-lethality biotechs (in a field killing cancer by exploiting its specific genetic weaknesses). WHY SYNTHETIC LETHALITY: many cancers are driven by LOST tumor-suppressor genes — which are hard to 'drug' (you can't restore a missing protein with an inhibitor); SYNTHETIC LETHALITY offers a clever route: two genes are 'synthetically lethal' if a cell survives losing EITHER one but DIES if it loses BOTH — so when a tumor has already lost one gene (e.g., a BRCA mutation that cripples DNA repair), a drug INHIBITING its synthetic-lethal PARTNER (e.g., PARP, another DNA-repair enzyme) selectively KILLS the cancer cells (which can't survive losing both) while sparing NORMAL cells (which still have the first gene) — a precise, biomarker-driven way to attack 'undruggable' losses. PARP inhibition in BRCA-mutant ovarian/breast cancer (Lynparza) is the validated proof-of-concept; the field now hunts NEW synthetic-lethal pairs. MAJOR HOLDERS: ASTRAZENECA/MERCK (PARP inhibitors — Lynparza/olaparib), REPARE THERAPEUTICS, TANGO THERAPEUTICS, IDEAYA, plus pharma. Synthetic-lethal targets, inhibitor compositions, biomarkers/patient selection, screening platforms, and combination/resistance are the core synthetic-lethality patent domains — and new targets, inhibitors, biomarkers, and screening are the open whitespace.

Synthetic-lethal-target innovations; inhibitor-composition innovations; screening-platform innovations; and mechanism innovations represent core synthetic-lethality patent domains — and discovering new lethal gene pairs, the drugs that exploit them, and the screens that find them are the foundational, high-value capabilities. SYNTHETIC-LETHAL-TARGET PATENTS: the specific gene/protein whose inhibition is LETHAL ONLY in a defined genetic context (the synthetic-lethal PARTNER of a commonly-lost cancer gene) — beyond PARP/BRCA, examples include WRN (Werner helicase) in microsatellite-instable (MSI) cancers, PRMT5/MTAP-deletion, POLθ, USP1, and others; identifying and validating a NEW synthetic-lethal target/interaction is core, high-value IP (the target — the lethal dependency in a genetic context — is the foundational discovery, and Repare/Tango are built on finding new ones); note targets/genes themselves face §101 limits, so claim the inhibition-in-context method/use. INHIBITOR-COMPOSITION PATENTS: the actual DRUG — a small molecule (or other modality) that INHIBITS the synthetic-lethal target; inhibitor composition-of-matter is core, high-value IP (the molecule is the product/drug — patentable composition, unlike the natural gene). SCREENING-PLATFORM PATENTS: the discovery ENGINE — CRISPR/RNAi FUNCTIONAL-GENOMICS screens (and computational/AI approaches) that systematically DISCOVER synthetic-lethal interactions across genetic backgrounds (Repare's SNIPRx, Tango's screens); screening-platform methods are high-value IP (the platform that finds new lethal pairs is a durable engine — though it overlaps CRISPR-screening tools, mind §101 for computational parts). MECHANISM PATENTS: methods exploiting the specific lethal mechanism (DNA-repair dependency, replication stress); mechanism methods are valuable. Synthetic-lethal targets, inhibitor compositions, screening platforms, and mechanism are the highest-value core IP because the lethal dependency, the drug exploiting it, and the engine discovering it are exactly what define synthetic-lethality oncology.

Biomarker/patient-selection innovations; §101-navigating innovations; combination/resistance innovations; and companion-diagnostic and indication innovations represent additional synthetic-lethality patent domains — and identifying which patients respond (the precision core), drafting eligible claims, and combinations are where clinical value and IP defensibility concentrate. BIOMARKER / PATIENT-SELECTION PATENTS: synthetic lethality is inherently PRECISION oncology — the drug only works in patients whose tumors have the defining GENETIC alteration (BRCA mutation, MSI status, MTAP deletion, HRD score), so the BIOMARKER selecting responders is essential; biomarker/patient-selection methods (and the genetic context defining the synthetic-lethal vulnerability) are high-value IP — BUT face §101 (Mayo natural-correlation) scrutiny (a gene-mutation-to-drug-response correlation can be deemed a natural correlation), so claim concrete technical methods (specific assay + treatment method), not the bare correlation. §101-NAVIGATING PATENTS: the genes/mutations and gene-response correlations are natural phenomena (§101/Mayo/Myriad-limited) — so durable IP is in the INHIBITOR composition (man-made molecule, clearly eligible) and METHODS OF TREATMENT (treating patients with biomarker X using drug Y — a concrete method), not the discovery/correlation itself; §101-aware claiming is critical, strategic IP. COMBINATION / RESISTANCE PATENTS: combining synthetic-lethal drugs with chemo/immunotherapy/other DNA-damage agents, and overcoming RESISTANCE (tumors evolve resistance — e.g., BRCA reversion); combination/resistance methods are high-value IP (combinations expand efficacy; resistance is a key clinical problem). COMPANION-DIAGNOSTIC / INDICATION PATENTS: the companion DIAGNOSTIC test identifying eligible patients, and specific indications; companion-Dx and indication methods are valuable. Biomarker/patient-selection, §101-robust claiming, combination/resistance, and companion-Dx are the highest-value application IP because selecting the right patients (with enforceable claims), combining, and beating resistance are exactly what make synthetic-lethality drugs effective precision medicines.

Synthetic lethality startup IP strategy must navigate AstraZeneca/Merck (PARP/Lynparza) and Repare/Tango/IDEAYA portfolios, the §101 natural-phenomenon problem (genes, mutations, and gene-response correlations are §101-limited — claim the inhibitor and treatment method, not the correlation/discovery), the target-discovery-vs-drug split (finding a new synthetic-lethal target vs developing the inhibitor — both rich, but the inhibitor is the cleanest IP), the biomarker/precision-oncology dependence (the drug only works in a genetic subset — biomarker and companion-Dx essential), the screening-platform overlap (CRISPR functional-genomics screens overlap CRISPR-screening tools — FTO), the resistance challenge, the heavy clinical/FDA path, and a landscape where synthetic-lethal targets, inhibitors, biomarkers, screening, and combinations are the durable assets; understand that genes/correlations are §101-limited, so the durable IP is in INHIBITOR compositions, methods of treatment (biomarker-defined), new synthetic-lethal targets/uses, screening platforms, and combinations — with the inhibitor molecule and §101-robust treatment-method claims often the real determinants, and that the inhibitor, validated target/biomarker, clinical efficacy, and §101-robust claims matter as much as patents; identify whitespace in new targets, inhibitors, and combinations. SYNTHETIC-LETHALITY STARTUP IP STRATEGY: INHIBITOR COMPOSITIONS, BIOMARKER-DEFINED TREATMENT METHODS, NEW SYNTHETIC-LETHAL TARGETS/USES, SCREENING PLATFORMS, AND COMBINATIONS ARE THE IP: patent inhibitor composition-of-matter, biomarker-defined methods of treatment, new synthetic-lethal target/uses, screening platforms, and combinations; §101 IS CENTRAL — CLAIM THE INHIBITOR + TREATMENT METHOD, NOT THE CORRELATION: genes/mutations and gene-to-drug-response correlations are natural phenomena (Mayo/Myriad-limited) — the durable IP is the man-made INHIBITOR (clearly eligible composition) and concrete METHODS OF TREATMENT (treat biomarker-X patients with drug-Y), not the discovery/correlation; THE INHIBITOR IS THE CLEANEST, CORE IP: composition-of-matter on the synthetic-lethal-target inhibitor is the strongest, most-eligible asset; NEW SYNTHETIC-LETHAL TARGETS ARE THE WHITESPACE (BEYOND PARP/BRCA): WRN/MSI, MTAP/PRMT5, POLθ, USP1, and others — discovering/validating new lethal dependencies (and claiming their inhibition-in-context) is high-value (Repare/Tango model); BIOMARKER/PATIENT-SELECTION IS ESSENTIAL (PRECISION ONCOLOGY): the drug only works in the defined genetic subset — biomarker + companion-Dx are essential (claim concrete assay+treatment methods, mind §101); SCREENING PLATFORM IS A DISCOVERY ENGINE (BUT WATCH CRISPR FTO): CRISPR/functional-genomics screens that find new pairs are a durable engine — but overlap CRISPR-tool IP (FTO); COMBINATIONS/RESISTANCE EXPAND VALUE: combinations and overcoming resistance (BRCA reversion) are high-value IP; CLINICAL/TARGET-VALIDATION/§101 MATTER AS MUCH AS PATENTS: the inhibitor, a validated target/biomarker, clinical efficacy, and enforceable (§101-robust) claims drive value; WHEN TO PATENT: NOVEL TARGET/INHIBITOR/BIOMARKER-METHOD/COMBINATION WITH MEASURED DATA + ELIGIBLE CLAIMS: file once a candidate shows measured results (synthetic-lethal validation in genetic context + inhibitor potency/selectivity + biomarker-defined efficacy + combination benefit) AND can be claimed §101-robustly (inhibitor + treatment method) — measured synthetic-lethal selectivity, inhibitor potency, biomarker-defined efficacy, and §101-robust claims are the critical synthetic-lethality IP metrics; KEY FTO CHECKLIST: AstraZeneca/Merck (PARP/Lynparza/olaparib); Repare (SNIPRx)/Tango/IDEAYA; synthetic-lethal target (WRN/MTAP-PRMT5/POLθ/USP1/etc.) inhibition-in-context; inhibitor composition-of-matter; biomarker/patient-selection (BRCA/MSI/MTAP/HRD) + companion-Dx (§101); §101 (inhibitor + treatment method vs natural correlation, Mayo/Myriad); CRISPR/functional-genomics screening platform (CRISPR-tool FTO); combination/resistance (BRCA reversion); indications; FDA/clinical path.